

Curriculum Vitae

Name: Dr Jeevan Kumar

Designation: Senior Consultant, Department of Clinical Hematology & BMT,

Tata Medical Centre, Kolkata

Address: Department of Clinical Hematology & BMT,

Tata Medical Center, 14 MAR(EW),

New Town, Rajarhat,

Kolkata-700160

EDUCATION QUALIFICATION

Degree	Institute	Board/ University
Clinical Hematology & Bone marrow transplant fellowship	Tata Medical Center	Tata Medical Center, Kolkata, India
Doctorate of National Board (DrNB) in Hematology (Gold Medalist)	Sir Ganga Ram Hospital, New Delhi, India	National Board of Examinations, New Delhi, India
MD in Internal Medicine	Government Medical College, Amritsar, Punjab, India	Baba Farid University of Health Sciences, Faridkot, Punjab, India
MBBS	Indira Gandhi Medical College, Shimla, Himachal Pradesh, India	Himachal Pradesh University, Shimla, Himachal Pradesh, India

PROFESSIONAL EXPERIENCE

Period	Name of Institution	Position held
2016-till date	Tata Medical Center, Kolkata, India	Senior Consultant in Department of Clinical Hematology & Bone Marrow Transplant
2014- 2016	Tata Medical Center, Kolkata, India	Clinical Hematology & Bone marrow transplant fellowship
2010-2011	Maharishi Markandeshwar Institute of Medical Sciences and Research, Mullana, Ambala, Haryana, India	Assistant Professor of Internal Medicine
2009-2010	Indira Gandhi Medical College, Shimla, Himachal Pradesh, India	Senior Resident in Department of Nephrology
2008-2009	Indira Gandhi Medical College, Shimla, Himachal Pradesh, India	Registrar in Department of Cardiology
2004-2005	Govt. Medical College & Hospital, Sector 32, Chandigarh, India	Medical Officer in Department of Community Medicine
2002-2003	Govt. Medical College & Hospital, Sector 32, Chandigarh, India	Junior resident in Department of Pediatrics and Medicine

THESIS AND RESEARCH

1. "Cytogenetic and Molecular Profile of Acute Myeloid Leukaemia in India" Thesis completed during the degree of Diplomate of National Board in Hematology. Studied cytogenetics along with FLT3 and NPM1 mutations in 44 AML patients.
2. "Evaluation of the clinical efficacy of Ramipril versus combination of Ramipril and Telmisartan in microalbuminuria in stage-II hypertensive patients" Thesis completed during the degree of MD in Medicine.

PAPER PRESENTATIONS

1. **Kumar J**, Pincha R, Radhakrishnan VS, Tamboli N, et al. Safety and Efficacy of Bortezomib-Pomalidomide-Dexamethasone (VPD) As Novel Induction Therapy in Newly-Diagnosed Multiple Myeloma: Updated Data from an Ongoing Single Arm Phase-II Investigator- Initiated Clinical Trial (PRIME Study). Blood (2023) 142 (Supplement 1): 6713.<https://doi.org/10.1182/blood-2023-186903>
2. Data of multiple myeloma patients from Indian Myeloma academic groupe (IMAGe) Registry: Indian Myeloma Congress 3rd annual conference -2020
3. Autologous stem cell transplantation in Mutliple Myeloma: experience of a single center from Eastern India. SOHO meeting 2019, Houston, US
4. FISH Analysis using CD138 Positively Selected Plasma Cells in Multiple Myeloma: A retrospective study from India. Indian Myeloma Congress 2018.
5. Analysis of chronic myeloid leukemia treatment of a tertiary care center. Leukemia Meet 2017- Lessons learnt from the Leukemia Clinics, Kolkata
6. Analysis of 53 patients with Autologous Stem Cell Transplantation for Multiple Myeloma from a tertiary care center in Eastern India. 16th International Myeloma Workshop, New Delhi, March 2017
7. "Autologous stem cell transplantation in Mutliple Myeloma"presented during Conference of Multiple Myeloma: State of the Art 2016, Chandigarh, India
8. "Cytogenetic and Molecular Profile of Acute Myeloid Leukaemia in India" presented during 54th National Conference of Indian Society of Hematology & Transfusion Medicine (ISHTM)-2013, Mumbai, India.
9. "Bortezomib plus Dexamethasone Induction Followed by Autologous Stem Cell Transplantation in Multiple Myeloma: A Study from India" presented during 54th National Conference of Indian Society of Hematology & Transfusion Medicine (ISHTM)-2013 Mumbai, India.
10. "Expression of CD20 in precursor B-cell acute lymphoblastic leukemia – An analysis of 100 cases" presented during 52nd National Conference of Indian Society of Hematology & Transfusion Medicine (ISHTM)-2011, Chandigarh, India.
11. "Profile of serum immunofixation electrophoresis in Multiple Myeloma – A study in a Tertiary Care centre" presented during 52nd National Conference of Indian Society of Hematology & Transfusion Medicine (ISHTM)-2011, Chandigarh, India.

PUBLICATIONS

1. **Kumar J**, Pincha R, Radhakrishnan VS, Tamboli N, et al. Safety and Efficacy of Bortezomib-Pomalidomide-Dexamethasone (VPD) As Novel Induction Therapy in Newly-Diagnosed Multiple Myeloma: Updated Data from an Ongoing Single Arm Phase-II Investigator- Initiated Clinical Trial (PRIME Study). *Blood* (2023) 142 (Supplement 1): 6713.<https://doi.org/10.1182/blood-2023-186903>
2. Kumar L, Melinkeri S, Ganesan P, **Kumar J**, et al. Daratumumab in Indian patients with relapsed and refractory multiple myeloma: a prospective, multicenter, phase IV study. *Future Oncol.* [doi/10.2217/fon-2023-0842](https://doi.org/10.2217/fon-2023-0842)
3. Ghosh S, Bhattacharya S, Goel G, Deshmukh RA, **Kumar J**, et al. Hematopoietic stem-cell transplantation in a zoo of multidrug-resistant organisms: Data from a cancer center in eastern India. *Transpl Infect Dis.* 2023; 25(Suppl. 1):e14072. <https://doi.org/10.1111/tid.14072>
4. Sardar SK, Goel G, Ghosal A, Bhattacharya S, **Kumar J**, et al. First case report of Cyclosporiasis from eastern India: Incidence of *Cyclospora cayentanensis* in a patient with unusual diarrheal symptoms. *J Infect Dev Ctries* 2023; 17(7):1037-1040. [doi:10.3855/jidc.17465](https://doi.org/10.3855/jidc.17465)
5. Radhakrishnan VS, Tamboli N, Das S, Kumar J, et al. Bortezomib-Pomalidomide-Dexamethasone (VPD) As Novel Induction Therapy in Newly-Diagnosed Multiple Myeloma: Early Safety Data from an Ongoing Single Arm Phase-II Investigator-Initiated Clinical Trial (PRIME Study) *Blood* (2021) 138 (Supplement 1): 2752. <https://doi.org/10.1182/blood-2021-151718>
6. **Kumar J**, Radhakrishnan VS, Nair R, Bhav S, Chandy M, et al. Blastic Plasmacytoid Dendritic Cell Neoplasm in a Young Female: Rare and Challenging. *Indian Journal of Medical and Pediatric Oncology.* 2020. DOI: 10.4103/ijmpo.ijmpo_143_19
7. **Kumar J**, Nair R, Radhakrishnan VS, Bhav S, Chandy M, et al. Autologous stem cell transplantation in Multiple Myeloma: experience of a single center from Eastern India. *Clinical Lymphoma, Myeloma & Leukemia*, 2019. 19: S124-S176. <https://doi.org/10.1016/j.clml.2019.07.393>
8. **Kumar J**, Nair R, Radhakrishnan VS, Bhav S, Chandy M, et al. Single center analysis of chronic myeloid leukemia treatment. *Indian J Hematol Blood Transfus* 33, 1–126 (2017). <https://doi.org/10.1007/s12288-017-0893>
9. **Kumar J**, Nair R, Chakrapani A, Bhav S, Chandy M, et al. Single Center Experience with Autologous Stem Cell Transplantation for Multiple Myeloma, a retrospective analysis. *Clinical Lymphoma, Myeloma & leukemia*. Feb 2017, 17; e72
10. Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, **Kumar J**, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-

label, phase 3 trial. *Lancet*. 2020;396:1563–1573. doi: 10.1016/S0140-6736(20)32292-3.

11. Abela O, Cicconi L, Locatelli F, **Kumar J**, Miguel A. Sanz, Francesco Lo Coco; Clinical Characteristics and Treatment Outcome of Acute Myeloid Leukemia with APL-like Morphology and Uncommon *RARA* Fusion Variants. *Blood* 2017; 130 (Supplement 1): 3860. doi: https://doi.org/10.1182/blood.V130.Suppl_1.3860.3860
12. Radhakrishnan VS, Nair R, **Kumar J**, Mallath M. Cachexia at Diagnosis adversely predicts outcomes in patients with Aggressive B-Cell NHL receiving standard of care treatment: A Prospective Observational Study from India. *Blood* 2019; 134 (Supplement_1): 2907. doi: <https://doi.org/10.1182/blood-2019-126295>
13. Kumar M, **Kumar J**, Harishankar A, Bhav S, Nair R, Bhattacharya S, Chandy M. Cytomegalovirus reactivation and disease amongst patients with allogeneic haematopoietic stem cell transplantation in Eastern India: Epidemiology, outcome and healthcare cost. *Indian Journal of Medical Microbiology*. 2018; 36: 1: 49-53
14. **Kumar J**, Minhas S, Khillan K, Bhargava M, Aggarwal S. Bortezomib plus dexamethasone induction followed by autologous stem cell transplantation in multiple myeloma: A study from India. *Asian Journal of Medical Sciences*. 2016; 7 (4): 44-48.
15. Nag, A., Radhakrishnan VS, **Kumar J**, Chandy M et al. Thalidomide in Patients with Transfusion-Dependent E-Beta Thalassemia Refractory to Hydroxyurea: A Single-Center Experience. *Indian J Hematol Blood Transfus* (2020). <https://doi.org/10.1007/s12288-020-01263-2>
16. Chowdhury MR, **Kumar J**, Chakrapani A, Bhav S, Krishnan S, Thambudurai R, Bhattacharya S, Chandy M. Low Incidence of Central Venous Catheter-Related Bloodstream Infections in Stem Cell Transplant Patients in Eastern India Despite High Community Burden of Multidrug-Resistant Pathogens. *Infect Control Hosp Epidemiol* 2016; 37:619–620.
17. Nag A, Radhakrishnan VS, **Kumar J**, Chandy M et al. Profile of Acute Graft-versus-Host-Disease of the Gastro-Intestinal Tract following Allogeneic Hematopoietic Cell Transplantation from a Tertiary Care Center in India. *Bone Marrow Transplant* 54, 144–619 (2019). <https://doi.org/10.1038/s41409-019-0559-4>
18. Radhakrishnan VS, Shah S, **Kumar J**, Bhav S, Nair R, Chandy M et al. Outcomes of high risk myeloid malignancies undergoing Hematopoietic Cell transplant in a tertiary Care facility: real world evidence from India. *Bone Marrow Transplant* 53, 145–805 (2019). <https://doi.org/10.1038/s41409-018-0354-7>

19. Radhakrishnan VS, **Kumar J**, Bhave S, Nair R, Chandy M et al. T-cell Replete Haploidentical Peripheral blood Hematopoietic cell transplant is associated with high incidence of cytokine release syndrome: Single Centre experience from India. Bone Marrow Transplant 53, 145–805 (2019). <https://doi.org/10.1038/s41409-018-0354-7>
20. Shah S, Radhakrishnan VS, **Kumar J**, Bhave S, Nair R, Chandy M et al. Myeloablative Conditioning Followed By T-Cell Replete Haploidentical Related Donor Peripheral Blood Stem Cell Transplant Using Post-Transplant Cyclophosphamide Immune Tolerance Approach for High Risk Haematological Malignancies: An Indian Perspective. Biol Blood Marrow Transplant 24 (2018) S291–S459
21. Gupta N, Parihar M, **Kumar J**, Bhave S, Chandy M, Mishra D, Arora N et al. FxCycle™ Based Ploidy Correlates with Cytogenetic Ploidy in B-Cell Acute Lymphoblastic Leukemia and Is Able to Detect the Aneuploid Minimal Residual Disease Clone. Cytometry B Clin Cytom 2019. 96:5: 359-367.
22. Gupta N , Pawar R, Parihar M, **Kumar J**, Nair R, Chandy M, Arora N, Mishra D et al. Spectrum and Immunophenotypic Profile of Acute Leukemia: A Tertiary Center Flow Cytometry Experience. Mediterr J Hematol Infect Dis 2019, 11(1): e2019017, DOI: <http://dx.doi.org/10.4084/MJHID.2019.017>
23. Modak K, Radhakrishnan VS, **Kumar J**, Nair R, Chandy M et al. Bridging R-ALL (Relapsed / Refractory Acute Lymphoblastic Leukemia) to a Haematopoietic Cell Transplant using InotuzumabOzagamycin. Indian J Hematol Blood Transfus 34, 1–396 (2018). <https://doi.org/10.1007/s12288-018-1037-7>
24. **Kumar J**, Chakrapani A, Bhave S, Nair R, Khosoo V, Chitrapur R, Mishra D, Arora N, Parihar M, Chandy M. Autologous stem cell transplantation in Multiple Myeloma: Analysis of 45 patients from a new stem cell unit from Eastern India. (Abstract) 2nd ISHBT-EHA Tutorial on myeloid malignancies and multiple myeloma. 2016.
25. **Kumar J**, Sachdeva A. Monitoring High risk areas: Cancer wards. In: Wattal C, Khardori N eds. Hospital infection prevention: Principles & Practices. 1st ed. New Delhi, India: Springer; 2014: 137-142.
26. **Kumar J**, Khan AA, Saraf A, Bhargava M. Expression of CD20 in B cell precursor acute lymphoblastic leukemia. Indian J Hematol Blood Transfus. (Jan –Mar) 2014, 30 (1) :16-18; doi: 10.1007/s12288-012-0216-1.
27. **Kumar J**, Arya V, Sachdeva A, Aggarwal S, Bhargava M. Cytogenetic and Molecular Profile of Acute Myeloid Leukaemia in India. Indian J Hematol Blood Transfus. 2013; 29(4): 281.
28. **Kumar J**, Bhargava M, Aggarwal S. Bevacizumab-induced reversible thrombocytopenia in a patient with adenocarcinoma of colon: Rare adverse effect of Bevacizumab. Case Rep Oncol Med. 2012; doi: 10.1155/2012/695430.

29. **Kumar J**, Khan AA, Kumar V, Bhargava M. Profile of serum immunofixation electrophoresis in Multiple Myeloma – A study in a Tertiary Care centre. Indian J Hematol Blood Transfus. 2011; 27(4): 222.
30. **Kumar J**, Singh G, Singh K, Sandhu PS. Evaluation of the efficacy of ramipril versus combination of ramipril and telmisartan in stage II hypertensive patients with microalbuminuria. Biomedicine. 2010; 30(3): 340-345.

CLINICAL TRIALS

1. Principal Investigator: A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (svd) versus bortezomib and dexamethasone (vd) in patients with relapsed or refractory multiple myeloma (RRMM), Karyopharm [Protocol ID: KCP-330-023]. Study completed.
2. Principal Investigator: A Phase II, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single Agent Belantamab Mafodotin (GSK2857916) in Participants with Relapsed or Refractory Multiple Myeloma (DREAMM14): Ongoing study.
3. Principal Investigator: A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase: Ongoing study.
4. Principal Investigator: Myeloma registry- Indian Myeloma academic groupe (IMAGe) Registry [Multicenteric] : Ongoing study.
5. Co Guide for DNB Thesis: Effect of Pomalidomide- Bortezomib-Dexamethasone Induction on MRD status in patients with newly diagnosed Multiple Myeloma (PRIME Study) : Ongoing study.
6. Co Investigator for DNB thesis: Acute Myeloid Leukemia: Exploring the feasibility of Multi-modal-Omics based Genomic characterization, MRD evaluation and Computational drug modelling to inform Disease management: Ongoing study.
7. Co Investigator: A multicentre retrospective medical record review study to describe real –world treatment patterns and safety among patients receiving Rituximab (Mabthera or Reditux) to treat B cell NHL in India: Study completed.
8. Co Investigator: A Phase 2b Open-Label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. [Protocol ID: KCP-330-009] : Study completed.

9. A Phase 1/2, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of DRL-1801 in Patients with RRMM (SWASTH). (Principal Investigator)
10. A randomized, 2-arm, phase 3 study of elranatamab (pf-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma after undergoing autologous stem-cell transplantation (MAGNETISMM 7). (Principal Investigator)
11. A randomized, 2-arm, phase 3 study of elranatamab (pf-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma after undergoing autologous stem-cell transplantation (MAGNETISMM 7). (Principal Investigator)
12. A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM). (Principal Investigator)
13. An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate its Safety in Indian Participants with Relapsed and Refractory Multiple Myeloma who have previously received at least 3 prior lines of therapy including an Immunomodulatory agent, a Proteasome Inhibitor and an AntiCD38 antibody and have demonstrated disease progression on the last therapy. (Principal Investigator)
14. A Double-Blind, Randomized clinical study of the efficacy and safety of monotherapy with BCD-264 and Darzalex® in subjects with Relapsed and Refractory Multiple Myeloma (DARVIVA). (Principal Investigator)
15. A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1). (Co-Investigator)
16. A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/ μ L). (Co-Investigator)
17. A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR108 in Patients with Relapsed Advanced Lymphoma (ASHA-1). (Co-Investigator)
18. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) (Co-Investigator)

CLINICAL RESEARCH EXPERIENCE

Indication	Phases	Duration	Role (s)	Status of the
------------	--------	----------	----------	---------------

		of the Trial		trial
Multiple Myeloma	III	3 years	Principal Investigator	Completed
Multiple Myeloma	II	3 years	Principal Investigator	Ongoing
CML	III	3 years	Principal Investigator	Completed
Myeloma	Registry	-	Principal Investigator	Ongoing
Myeloma	II	3 years	Principal Investigator	Ongoing
Myeloma	I	5 years	Principal Investigator	Ongoing
AML	Observational/ Analytical	4 years	Co Investigator	Ongoing
Lymphoma	Registry	9 years	Co Investigator	Completed
DLBCL	II		Co Investigator	Completed
DLBCL	III	3 years	Principal Investigator	Completed
Multiple Myeloma	IV	3 years	Principal Investigator	Completed
CLL & MCL	IV	3 years	Co Investigator	Ongoing
CLL & MCL	IV	3 years	Co Investigator	Ongoing
MDS	III	5 years	Co Investigator	Ongoing
CML	I	3 years	Co Investigator	Ongoing
MYELOMA	1/2	5	Principal Investigator	Ongoing

Seon Kim
19.02.2026